FDA Clears Teleflex’s Arrow JACC With Chloragard Technology and Tunneler


October 12, 2016—Teleflex Incorporated announced that it has received US Food and Drug Administration 510(k) clearance to market the company’s Arrow JACC (jugular axillosubclavian central catheter) with Chloragard technology and TightTrack tunneler.

According to Teleflex, the Arrow JACC with Chloragard is a long-term, tunneled, small French-size antithrombogenic and antimicrobial central venous catheter designed to meet the needs of patients throughout their course of therapy or illness. The catheter is also designed for use with high-pressure injection for diagnostic studies.

Arrow JACC with Chloragard protects against catheter occlusion, phlebitis, and intimal hyperplasia for up to 30 days. It also enables caregivers to effectively and economically preserve vessel access and care for end-stage renal disease patients, stated the company.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.